2006
Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increase
2002
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Rainey PM, Friedland GH, Snidow JW, McCance‐Katz E, Mitchell SM, Andrews L, Lane B, Jatlow P. The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects. American Journal On Addictions 2002, 11: 66-74. PMID: 11876585, DOI: 10.1080/10550490252801657.Peer-Reviewed Original ResearchConceptsSerum concentrationsCombination tabletSerum concentration-time curveMethadone dose changesMethadone serum concentrationsMaximum serum concentrationOpiate-dependent subjectsConcentration-time curveVolume of distributionCombination pharmacotherapyMethadone pharmacokineticsTerminal eliminationCo-administrationDose changesMean areaSignificant differencesPharmacokineticsSubjectsSubject studyHIVPharmacotherapyPatientsAdministration
1996
Stavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials